methyl 4-azido-3,4-dihydro-2H-chromene-7-carboxylate | 361370-00-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: methyl 4-azido-3,4-dihydro-2H-chromene-7-carboxylate
• CAS: 361370-00-5
• 化学式: C₁₁H₁₁N₃O₃
• 分子量: 233.227
• InChiKey: RAQURCRPOQOCEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  49.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 4-azido-3,4-dihydro-2H-chromene-7-carboxylate 在 lithium aluminium tetrahydride 、 silica-supported carbodiimide 、 1-羟基苯并三唑 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 (S)-N-((RS)-7-(hydroxymethyl)-2,3-dihydro-2H-chromen-4-yl)-3-(naphthalene-2-sulfonamido)-3-phenylpropanamide
  参考文献：
  名称：

  Identification of a Nonpeptidic and Conformationally Restricted Bradykinin B1 Receptor Antagonist with Anti-Inflammatory Activity

  摘要：

  We report the discovery of chroman 28, a potent and selective antagonist of human, nonhuman primate, rat, and rabbit bradykinin B1 receptors (0.4-17 nM). At 90 mg/kg s.c., 28 decreased plasma extravasation in two rodent models of inflammation. A novel method to calculate entropy is introduced and ascribed similar to 30% of the gained affinity between "flexible" 4 (K-i = 132 nM) and "rigid" 28 (K-i = 0.77 nM) to decreased conformational entropy.

  DOI：

  10.1021/jm061224g
• 作为产物：
  描述：

  4-氧代苯并二氢吡喃-7-羧酸甲酯 在 sodium tetrahydroborate 、 二苯基膦叠氮化物 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 0.08h， 生成 methyl 4-azido-3,4-dihydro-2H-chromene-7-carboxylate
  参考文献：
  名称：

  Identification of a Nonpeptidic and Conformationally Restricted Bradykinin B1 Receptor Antagonist with Anti-Inflammatory Activity

  摘要：

  We report the discovery of chroman 28, a potent and selective antagonist of human, nonhuman primate, rat, and rabbit bradykinin B1 receptors (0.4-17 nM). At 90 mg/kg s.c., 28 decreased plasma extravasation in two rodent models of inflammation. A novel method to calculate entropy is introduced and ascribed similar to 30% of the gained affinity between "flexible" 4 (K-i = 132 nM) and "rigid" 28 (K-i = 0.77 nM) to decreased conformational entropy.

  DOI：

  10.1021/jm061224g

文献信息

• Amide compounds and use thereof
  申请人：——

  公开号：US20030158413A1

  公开（公告）日：2003-08-21

  The present invention relates to an amide compound of the formula 1 wherein R 1 is a hydrogen and the like, R 2 is a hydrogen and the like, X is SO 2 and the like, Y is the formula (III) and the like and a is 2, an isomer thereof or pharmaceutically acceptable salts thereof. The compound of the present invention shows a remarkable and selective Rho kinase inhibitory action, is free of problematic toxicity, shows fine oral absorption and drug kinetics (absorption, distribution, metabolism, excretion and the like of the drug), and shows superior properties (e.g., stability etc.) as a compound. Accordingly, it can be used as a therapeutic drug for various diseases in which Rho kinase is involved.

  本发明涉及一种式1的酰胺化合物，其中R1为氢等，R2为氢等，X为SO2等，Y为式（III）等，a为2，其异构体或其药学上可接受的盐。本发明的化合物显示出显著且选择性的Rho激酶抑制作用，不具有有毒性问题，显示出良好的口服吸收和药物动力学（药物的吸收、分布、代谢、排泄等），并且显示出优越的特性（例如稳定性等）作为一种化合物。因此，它可以作为治疗涉及Rho激酶的各种疾病的治疗药物。
• Triazoles and methods of use
  申请人：Aya Toshihiro

  公开号：US20060100213A1

  公开（公告）日：2006-05-11

  Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的化合物对于治疗疼痛和疾病，例如炎症介导性疾病具有有效性。本发明涵盖了新型化合物、类似物、前药和其药学上可接受的衍生物、制药组合物以及预防和治疗涉及疼痛、炎症等疾病和其他疾病或病况的方法。本发明还涉及制备这种化合物的过程以及在这种过程中有用的中间体。
• Novel B1 bradykinin receptor antagonists
  申请人：Askew C. Benny

  公开号：US20060100216A1

  公开（公告）日：2006-05-11

  The invention encompasses novel compounds and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for treatment of diseases mediated by B1 bradykinin receptor.

  这项发明涵盖了新型化合物及其药物可接受的衍生物，药物组合物和治疗通过B1-Bradykinin受体介导的疾病的方法。
• AMIDE COMPOUNDS AND USE THEREOF
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1270570A1

  公开（公告）日：2003-01-02

  The present invention relates to an amide compound of the formula wherein R1 is a hydrogen and the like, R2 is a hydrogen and the like, X is SO2 and the like, Y is the formula (III) and the like and a is 2, an isomer thereof or pharmaceutically acceptable salts thereof. The compound of the present invention shows a remarkable and selective Rho kinase inhibitory action, is free of problematic toxicity, shows fine oral absorption and drug kinetics (absorption, distribution, metabolism, excretion and the like of the drug), and shows superior properties (e.g., stability etc.) as a compound. Accordingly, it can be used as a therapeutic drug for various diseases in which Rho kinase is involved.

  本发明涉及一种如下式的酰胺化合物 其中 R1 为氢等，R2 为氢等，X 为 SO2 等，Y 为式（III）等，a 为 2、其异构体或其药学上可接受的盐。本发明的化合物具有显著和选择性的 Rho 激酶抑制作用，无毒性问题，口服吸收和药物动力学（药物的吸收、分布、代谢、排泄等）良好，并显示出作为化合物的优越性能（如稳定性等）。因此，它可以作为一种治疗药物，用于治疗 Rho 激酶参与的各种疾病。
• TRIAZOLES AND THEIR USE AS BRADYKININ B1 RECEPTOR ANTAGONISTS
  申请人：Amgen, Inc

  公开号：EP1817306A1

  公开（公告）日：2007-08-15